Select Language
EGF R
EGF R Overview
| English Name | Epidermal growth factor receptor erbB1 | Approved Drugs | 34 |
| Drugs in Clinical Trials | 188 | Target Synonym | Epidermal Growth Factor Receptor (Avian Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog)，Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog (Avian)，Avian Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog，Epidermal Growth Factor Receptor Tyrosine Kinase Domain，Cell Proliferation-Inducing Protein 61，Cell Growth Inhibiting Protein 40，EC 2.7.10.1，NISBD2，PIG61，MENA，EC:2.7.10.1，EC 2.7.10，Receptor tyrosine-protein kinase erbB-1，Proto-oncogene c-ErbB-1，Epidermal growth factor receptor，EGFR，Erb-B2 Receptor Tyrosine Kinase 1，ERBB1，ERBB，HER1 |
| Highest Development Stage | Approved | ||
| English Name | Epidermal growth factor receptor erbB1 |
| Target Synonym | Epidermal Growth Factor Receptor (Avian Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog)，Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog (Avian)，Avian Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog，Epidermal Growth Factor Receptor Tyrosine Kinase Domain，Cell Proliferation-Inducing Protein 61，Cell Growth Inhibiting Protein 40，EC 2.7.10.1，NISBD2，PIG61，MENA，EC:2.7.10.1，EC 2.7.10，Receptor tyrosine-protein kinase erbB-1，Proto-oncogene c-ErbB-1，Epidermal growth factor receptor，EGFR，Erb-B2 Receptor Tyrosine Kinase 1，ERBB1，ERBB，HER1 |
| Approved Drugs | 34 |
| Drugs in Clinical Trials | 188 |
| Highest Development Stage | Approved |
EGF R Product List
- Product Category
Protein (19)Beads (1)Antibody (1)Kits (1)Cell (1)
- Product Status
Launched (23)
- Species
Human (14)Mouse (4)Rhesus macaque (2)Rabbit (3)
- Tag
His Tag (9)Fc Tag (4)His Tag & Avi Tag (2)- (4)Llama IgG Fc Tag (1)Fc Tag & Avi Tag (2)Tag Free (1)
- Conjugate
Unconjugated (11)Biotin-labeled (4)FITC Labeled (2)- (3)PE Labeled (2)APC Labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature | Order Now |
|---|---|---|---|---|---|---|---|
HOT EGR-H5222 |  Human | HEK293 | Human EGF R Protein, His Tag (MALS verified) |  |  |  |  Add to Cart |
HOT EGR-H5252 | Human | HEK293 | Human EGF R Protein, Fc Tag (MALS verified) |  | | | Add to Cart |
HOT EGR-H82E3 | Human | HEK293 | Biotinylated Human EGF R Protein, His,Avitag™ (MALS verified) |  | | | Add to Cart |
HOT EGR-H82F8 | Human | HEK293 | Biotinylated Human EGF R Protein, Fc,Avitag™ (MALS verified) |  | | | Add to Cart |
HOT EGR-HA2H8 | Human | HEK293 | APC-Labeled Human EGF R Protein, His TagStar Staining | Add to Cart | |||
CHEK-ATP148 | Human | HEK293 | HEK293/Human EGF R Stable Cell Line |  | Add to Cart | ||
EGR-H5213 | Human | HEK293 | Human EGF R Protein, Tag Free (MALS verified) |  | | | Add to Cart |
EGR-H522a | Human | HEK293 | Human EGF R Protein, His Tag, low endotoxin (MALS verified) |  | | | Add to Cart |
EGR-H5259 | Human | HEK293 | Human EGF R Protein, Llama IgG2b Fc Tag, low endotoxin (MALS verified) |  | | | Add to Cart |
EGR-HF256 | Human | HEK293 | FITC-Labeled Human EGF R Protein, Fc Tag |  | | | Add to Cart |
Total: 23
- 1
- 2
- 3
EGF R Background
The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer.
EGF R Synonyms
EGFR,ERBB,ERBB1,HER1,PIG61,mENA
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| PLB-1004 | PLB-1004 | Phase 3 Clinical | Beijing Avistone Pharmaceuticals Biotechnology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| YK-029A | YK-029A; YK-209A; YK-209-A; YK-029-A | Phase 3 Clinical | Hainan Yuekang Biomedicine Co Ltd | Drug-Related Side Effects and Adverse Reactions; Carcinoma, Non-Small-Cell Lung | Details |
| Petosemtamab | MCLA-158 | Phase 3 Clinical | Merus Nv | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Olafertinib | CK-101; RX-518; CS-2481; EGFR-IN-3 | Phase 3 Clinical | Suzhou Neupharma Co Ltd | Lung Diseases; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
| Cetuximab biosimilar (AlphaMab) | KN-005 | Phase 3 Clinical | Suzhou Alphamab Co Ltd | Head and Neck Neoplasms; Anus Neoplasms; Urinary Bladder Neoplasms; Colorectal Neoplasms | Details |
| HA121-28 | HA121-28; SYHA121-28 | Phase 3 Clinical | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd | Biliary Tract Neoplasms; Solid tumours; Esophageal Neoplasms; Neoplasms; Medullary thyroid cancer (MTC); Bile Duct Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Nimotuzumab biosimilar (El Kendi Pharmaceuticals Manufacturing) | Phase 3 Clinical | El Kendi Pharmaceuticals | Uterine Cervical Neoplasms | Details | |
| Cetuximab biosimilar (AMPO Biotechnology) | Phase 3 Clinical | Ampo Biotechnology Inc | Colorectal Neoplasms | Details | |
| Cetuximab biosimilar (R-Pharm) | RPH-002 | Phase 3 Clinical | R-Pharm | Head and Neck Neoplasms; Pancreatic Neoplasms | Details |
| QL1203 | QL-1203 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Colorectal Neoplasms | Details |
| BEBT-109 | BEBT-109 | Phase 3 Clinical | Guangzhou BeBetter Medicine Technology Co | Carcinoma, Non-Small-Cell Lung | Details |
| Immunomodulatory progenitor cell therapy (Celixir) | Phase 3 Clinical | Celixir | Endomyocardial Fibrosis; Cardiomyopathies | Details | |
| Izalontamab | SI-B001; SI-1X6.4 | Phase 3 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Head and Neck Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms, Glandular and Epithelial; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung | Details |
| Ruserontinib | SKLB-1028 | Phase 3 Clinical | Sichuan University, CSPC Pharmaceutical Group Ltd | Solid tumours; Leukemia, Promyelocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute | Details |
| Varlitinib Ditosylate | SPS-4370; ASLAN-001; ARRY-334543; ARRY-543; QBT-01 | Phase 3 Clinical | Array Biopharma | Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Cholangiocarcinoma; Bile Duct Neoplasms; Metastatic breast cancer | Details |
| Becotatug | JMT-101 | Phase 3 Clinical | Shanghai Jmt-Bio Inc | Solid tumours; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| HS-20117 | HS-20117; PM1080; PM-1080 | Phase 3 Clinical | Biotheus Inc | Solid tumours; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| SYS-6010 | SYS-6010; CPO-301; CPO301; SYS6010 | Phase 3 Clinical | Jushi Biopharmaceutical Co Ltd | Solid tumours; Small Cell Lung Carcinoma; Neoplasms; Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| IAE-0972 | IAE-0972 | Phase 3 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Nasopharyngeal Carcinoma; Carcinoma, Hepatocellular; Neoplasm Metastasis | Details |
| BAY-2927088 | BAY-2927088; BAY2927088 | Phase 3 Clinical | Bayer AG, Broad Institute, Harvard University | Solid tumours; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
| Izalontamab brengitecan | BMS-986507; BL-B01D1 | Phase 3 Clinical | Sichuan Baili Pharmaceutical Co Ltd, SystImmune | Chordoma; Uterine Cervical Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Metastatic breast cancer; Colorectal Neoplasms; Urologic Neoplasms; Breast Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Digestive System Neoplasms; Carcinoma, Transitional Cell; Nasopharyngeal Neoplasms; Small Cell Lung Carcinoma; Glioblastoma; Triple Negative Breast Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms, Fibroepithelial | Details |
| Nimotuzumab biosimilar (IBC Generium) | Phase 3 Clinical | International Biotechnology Center Generium Llc | Head and Neck Neoplasms | Details | |
| Depatuxizumab mafodotin | ABT-414; ABT-414/806 | Phase 3 Clinical | Abbvie Inc | Glioblastoma; Gliosarcoma; Carcinoma, Squamous Cell; Glioma | Details |
| EG-007 | EG-007 | Phase 3 Clinical | Shenzhen Aigelin Pharmaceutical Co Ltd | Endometrial Neoplasms | Details |
| Larotinib Mesylate | Z-650 | Phase 3 Clinical | Guangdong Dongyangguang Pharmaceutical Co Ltd | Solid tumours; Esophageal Neoplasms; Pancreatic Neoplasms; Esophageal Squamous Cell Carcinoma | Details |
| Ametumumab | SY-101 | Phase 2 Clinical | Institute of Bioengineering Academy of Military Medical Sciences Chinese People's Liberation Army, Shanghai Serum Bio-Technology Co Ltd | Solid tumours; Colorectal Neoplasms | Details |
| BB-401 | BB-401 | Phase 2 Clinical | Benitec Biopharma Ltd | Squamous Cell Carcinoma of Head and Neck | Details |
| Sutetinib Maleate | Phase 2 Clinical | Jiangsu Maidu Pharmaceutical R & D Co Ltd, Jiangsu Suzhong Pharma Group Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details | |
| GC-1118A | GC-1118; GC-1118A | Phase 2 Clinical | GC Biopharma Corp | Solid tumours; Stomach Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis | Details |
| Durvalumab/Gefitinib | Phase 2 Clinical | Medimmune | Carcinoma, Non-Small-Cell Lung | Details | |
| Pamvatamig | MCLA-129 | Phase 2 Clinical | Merus Nv | Solid tumours; Head and Neck Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| JNJ-26483327 | JNJ-26483327; MTKi-327; BGB-102 | Phase 2 Clinical | Johnson & Johnson | Solid tumours; Neoplasms; Macular Degeneration | Details |
| HER-1 vaccine (Center of Molecular Immunology) | HER1-ECD; HER1-VSSP; HER-1-ECD-VSSP | Phase 2 Clinical | Center Of Molecular Immunology | Neoplasms | Details |
| WSD-0922 | WSD0922; WSD-0922 | Phase 2 Clinical | Wayshine Biopharm International Ltd | Glioblastoma; Neoplasms; Astrocytoma; Carcinoma, Non-Small-Cell Lung | Details |
| AFM-24 | AFM-24 | Phase 2 Clinical | Affimed | Solid tumours | Details |
| C225-ILS-DOX | C225-ILs-dox | Phase 2 Clinical | Universitaetsspitals Basel | Breast Neoplasms | Details |
| Nazartinib | EGF-816; EGFRmut-TKI EGF816 | Phase 2 Clinical | Novartis Pharma Ag | Bronchial Neoplasms; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
| Sapitinib | AZD-8931 | Phase 2 Clinical | Astrazeneca Plc | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Metastatic breast cancer; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
| Tesevatinib | XL-647; KD-020; KD-019; EXEL-7647 | Phase 2 Clinical | Exelixis Inc | Neoplasms; Glioblastoma; Breast Neoplasms; Brain Neoplasms; Polycystic Kidney, Autosomal Dominant; Brain metastases; Neoplasm Metastasis; Polycystic Kidney, Autosomal Recessive; Carcinoma, Non-Small-Cell Lung | Details |
| Futuximab/Modotuximab | Sym-004; S95026; S-95026; 992-and-1024 | Phase 2 Clinical | Symphogen A/S | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Colorectal Neoplasms; Glioma | Details |
| BB-101 (Blue Blood Biotech/National Cheng Kung University) | BB-101 | Phase 2 Clinical | National Cheng Kung University, Blue Blood Biotech Corp | Diabetic Foot | Details |
| DBPR-112 | ABT-101; DBPR-112 | Phase 2 Clinical | National Health Research Institutes | Solid tumours; Head and Neck Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Panitumumab-IRDye800CW (Stanford University) | Phase 2 Clinical | Stanford University | Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Brain Neoplasms | Details | |
| AMX-3009 Maleate | AMX-3009; AMX3009马来酸 | Phase 2 Clinical | Anrun Medicine Technology (Suzhou) Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
| Allitinib Tosylate | AST-6; ALS-1306; AST-1306 | Phase 2 Clinical | Shanghai Allist Pharmaceutical Technology Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Demupitamab | SCT-200 | Phase 2 Clinical | SinoCelltech Ltd | Head and Neck Neoplasms; Solid tumours; Biliary Tract Neoplasms; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Neoplasms; Colorectal Neoplasms; Gallbladder Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
| Cetuximab-IRDye800CW (University Medical Center Groningen) | Phase 2 Clinical | Umcg The University Medical Center Groningen | Rectal Neoplasms; Penile Neoplasms; Lung Neoplasms | Details | |
| Selatinib Ditosilate | QLNC-120 | Phase 2 Clinical | Qilu Antibiotics (Linyi) Pharmaceutical Co Ltd, Qilu Pharmaceutical Co Ltd | Breast Neoplasms | Details |
| Pimurutamab | HLX-07 | Phase 2 Clinical | Shanghai Henlius Biotech Inc | Solid tumours; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Rectal Neoplasms; Esophageal Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Basosquamous; Carcinoma, Adenosquamous; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| NRC-2694 | NRC-2694; NRC-2694A; NRC-2694-A | Phase 2 Clinical | Natco Pharma | Carcinoma; Squamous Cell Carcinoma of Head and Neck | Details |
| Bafisontamab | FIT-013a; EMB-01 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | Biliary Tract Neoplasms; Liver Neoplasms; Stomach Neoplasms; Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Gastrointestinal Neoplasms | Details |
| Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian) | CPGJ-602; 602; CPGJ602; CPGJ 602 | Phase 2 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Colorectal Neoplasms | Details |
| GB-263 | GB-263; GB-263T | Phase 2 Clinical | Genor Biopharma Co Ltd | Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| ORIC-114 | ORIC-114; VRN-07 | Phase 2 Clinical | Voronoi Inc | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| WJ-13404 | WJ-13404; JS-113; WJ-004 | Phase 2 Clinical | Wigen Biomedicine technology (Shanghai) Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| BDTX-1535 | BDTX-1535 | Phase 2 Clinical | Black Diamond Therapeutics Inc | Glioblastoma; Glioma; Carcinoma, Non-Small-Cell Lung | Details |
| BH-30643 | BH-30643 | Phase 2 Clinical | BlossomHill Therapeutics Inc | Carcinoma, Non-Small-Cell Lung | Details |
| Anti-CD3 x Anti-EGFR Bispecific Antibody (EGFRBi) Armed Fresh Peripheral Blood Mononuclear Cells therapy(University Of Virginia) | Phase 2 Clinical | University Of Virginia | Pancreatic Neoplasms | Details | |
| WSD-0922-FU | WSD0922-FU; WSD-0922-FU | Phase 2 Clinical | Wayshine Biopharm International Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| Neratinib (Fukang (Shanghai) Health Technology) | CVL009; CVL-009 | Phase 2 Clinical | Fukang (Shanghai) Health Technology Co Ltd | Solid tumours; Uterine Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| PRO-1286 | PRO-1286; GEN1286; GEN-1286 | Phase 2 Clinical | ProfoundBio (Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
| TRX-221 | TRX-221 | Phase 2 Clinical | Therapex Corp | Carcinoma, Non-Small-Cell Lung | Details |
| PH-009-1 | PH-009-1; PH009-1 | Phase 2 Clinical | Suzhou Puhe Pharmaceutical Technology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| E-EDV-D682 | PNU-15982; E-EDV-D682; EGFR-EDV-PNU-15982 | Phase 2 Clinical | Engeneic Ltd | Pancreatic Neoplasms | Details |
| IBI334 | IBI334; IBI-334 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
| SHR-9839 | SHR-9839; SHR9839 | Phase 2 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Solid tumours; Colorectal Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
| DF9001 | DF-9001 | Phase 2 Clinical | Dragonfly Therapeutics Llc | Solid tumours | Details |
| DWP-708 | DWP-708 | Phase 2 Clinical | Daewoong Pharmaceutical Co Ltd | Acneiform Eruptions | Details |
| BBT-207 | BBT-207 | Phase 2 Clinical | Bridge Biotherapeutics Inc | Carcinoma, Non-Small-Cell Lung | Details |
| H-002 | H-002 | Phase 2 Clinical | Nanjing Hongyun Biological Technology Co Ltd | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| DAJH-1050766 | DAJH1050766; DAJH-1050766 | Phase 2 Clinical | Chengdu Diao Jiuhong Pharmaceutical Factory | Carcinoma, Non-Small-Cell Lung | Details |
| Anti-CTLA-4/PD-1 expressing EGFR-CAR-T | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Solid tumours | Details | |
| Anti-EGFR CAR-T cell therapy (Beijing Pregene) | Phase 2 Clinical | Colorectal Neoplasms | Details | ||
| HS-10375 | HS-10375 | Phase 2 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| SMET-12 | SMET-12 | Phase 2 Clinical | Zhejiang Shimai Pharmaceutical Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| EO-1001 | NT-113; APL-122 | Phase 2 Clinical | Edison Pharmaceuticals Inc | Neoplasms | Details |
| TAK-186 | EGFR x CD3 COBRA; MVC-101; TAK-186 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| AP-L1898 | JS111; WJ-002; AP-L1898 | Phase 2 Clinical | Wigen Biomedicine technology (Shanghai) Co Ltd | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| BPI-361175 | BPI-361175 | Phase 2 Clinical | Betta Pharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| CKD-702 | Phase 2 Clinical | Chong Kun Dang Pharmaceutical Corp | Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| REGN-7075 | REGN-7075 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| JRF-103 | JRF103; JRF-103 | Phase 2 Clinical | Shenzhen Jinrui Foundation Biotechnology Co Ltd | Solid tumours | Details |
| Anti-EGFR-IL-dox (Swiss Group for Clinical Cancer Research) | Phase 2 Clinical | Schweizerische Arbeitsgemeinschaft Für Klinische Krebsforschung | Breast Neoplasms | Details | |
| Epertinib | S-222611 | Phase 2 Clinical | Shionogi & Co Ltd | Neoplasms | Details |
| Pirotinib Hydrochloride | KBP-5209 | Phase 2 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Solid tumours; Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Humanized anti-EGFR monoclonal antibody (Hualan Biological Engineering/Henan shengming biotechnology) | Phase 2 Clinical | Henan Shengming Biotechnology Research Institute Co Ltd, Hualan Genetic Engineering Co Ltd | Colorectal Neoplasms | Details | |
| Anti-CD3/anti-EGFR -activated T cells (Barbara Ann Karmanos Cancer Institute) | Phase 2 Clinical | Barbara Ann Karmanos Cancer Institute, University Of Virginia | Glioblastoma; Pancreatic Neoplasms | Details | |
| Ascorbic Acid/Menadione | Phase 2 Clinical | Ic-Medtech Co, Summa Health System | Joint Diseases; Prostatic Neoplasms | Details | |
| Cetuximab biosimilar (Guilin Sanjin) | CDP-1; BC-001 | Phase 1 Clinical | Dragonboat Biopharmaceutical, Guilin Sanjin Pharmaceutical Co Ltd | Solid tumours; Neoplasms; Colorectal Neoplasms | Details |
| TQB3804 | TQB-3804 | Phase 1 Clinical | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| D2C7-IT | D2C7-(scdsFv)-PE38 KDEL; scds-D2C7 -PE38KDEL; D2C7-Immunotoxin; D2C7-IT | Phase 1 Clinical | Istari Oncology Inc, Duke University | Glioblastoma; Glioma | Details |
| SC-CAR4BRAIN | Phase 1 Clinical | Seattle Children'S Hospital | Sarcoma, Synovial; Neoplasms, Germ Cell and Embryonal; Diffuse Intrinsic Pontine Glioma; Sarcoma, Clear Cell; Osteosarcoma; Retinoblastoma; Neuroblastoma; Neurofibrosarcoma; Sarcoma, Ewing; Sarcoma; Solid tumours; Central Nervous System Neoplasms; Wilms Tumor; Carcinoma; Rhabdoid Tumor; Hepatoblastoma; Diffuse midline glioma; Desmoplastic Small Round Cell Tumor; Rhabdomyosarcoma | Details | |
| BPI-15086 | BPI-15086; BPI-15000 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| Recombinant anti-human EGFR antibody/IL-10 bispecific Fc fusion protein(Dingfu Biotarget) | CmAb-(IL10)2; DF203; DF-203 | Phase 1 Clinical | Dingfu Biotarget Co Ltd | Solid tumours | Details |
| MP-0274 | DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 | Phase 1 Clinical | Molecular Partners Ag | Neoplasms | Details |
| SYN-004 (Synermore Biologics) | LR-004; SYN-004 | Phase 1 Clinical | Lonn Ryonn Pharma Ltd, Synermore Biologics (Suzhou) Co Ltd | Solid tumours; Carcinoma; Lymphoma, Large B-Cell, Diffuse; Colorectal Neoplasms | Details |
| KY-1701 | KY-1701 | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Breast Neoplasms | Details |
| Simotinib Hydrochloride | AL-6802; SIM-6802 | Phase 1 Clinical | Jiangsu Simcere Pharmaceutical Co Ltd, Advenchen Laboratories Llc | Carcinoma, Non-Small-Cell Lung | Details |
| Double-deleted Vaccinia Virus Plus CD/ SMR | JX-929; vvDD-CDSR | Phase 1 Clinical | Sillajen Inc | Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma | Details |
| TQ-B3395 | TQ-B3395; CT-1495; TQ-B-3395 | Phase 1 Clinical | Beijing Centaurus Biopharma Co Ltd | Neoplasms; Breast Neoplasms | Details |
| Cetuximab biosimilar (Shanghai Henlius Biotech) | HLX-05; JZB-29; JZB-28 | Phase 1 Clinical | Shanghai Henlius Biotech Inc | Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms | Details |
| Recombinant chimeric anti-EGFR monoclonal antibody (Zhejiang Xinwei Shengke Biotechnology) | Phase 1 Clinical | Zhejiang Xinweishengke Biotechnology Co Ltd | Esophageal Neoplasms | Details | |
| Anti-EGFR-bispecific antibody armed activated T-cell therapy (Memorial Sloan Kettering Cancer Center) | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Pancreatic Neoplasms | Details | |
| [89Zr]Panitumumab | Phase 1 Clinical | Vanderbilt-Ingram Cancer Center, University Of Alabama At Birmingham, Stanford University | Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Colonic Neoplasms | Details | |
| Recombinant chimeric anti-EGFR monoclonal antibody (Qilu Pharmaceutical) | QL-1105 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | Details |
| EGFRvIII-CAR | Phase 1 Clinical | Duke University Medical Center | Glioblastoma | Details | |
| 14C-labeled poziotinib | Phase 1 Clinical | Spectrum Pharmaceuticals | Solid tumours | Details | |
| Puvitinib | Phase 1 Clinical | Suzhou Teligene Ltd | Solid tumours | Details | |
| Betatinib | TL-512 | Phase 1 Clinical | Aspedia Llc, Suzhou Teligene Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| KSP-QRH-E3-IRDye800 | Phase 1 Clinical | University Of Michigan | Cholangiocarcinoma | Details | |
| Hemay-020 | Hemay-020 | Phase 1 Clinical | Tianjin Hemay Pharmaceutical Co Ltd, Hainan General Sanyang Pharmaceutical Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| Erlotinib gel (Sol-Gel Technologies) | SGT-210 | Phase 1 Clinical | Sol Gel Technologies Pte Ltd | Keratosis | Details |
| ZN-e4 | ZN-e4; KP-673 | Phase 1 Clinical | Zentalis Pharmaceuticals LLC, Zeno Pharma | Carcinoma, Non-Small-Cell Lung | Details |
| LY-01010 | LY-01010 | Phase 1 Clinical | Luye Pharma Group Ltd | Breast Neoplasms | Details |
| PB-357 | PB-357 | Phase 1 Clinical | Pfizer Inc | Neoplasms | Details |
| ZSP-0391 | ZSP-0391 | Phase 1 Clinical | Wuxi Apptec Co Ltd, Guangdong Zhongsheng Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| Neptinib Di-P-methylbenzenesulfonate | Phase 1 Clinical | Shenzhen Neptunus Pharmaceutical Research Institute Co Ltd | Stomach Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| QRH-882260 | QRH-882260 | Phase 1 Clinical | University Of Michigan | Cholangiocarcinoma | Details |
| Serclutamab talirine | ABBV-321 | Phase 1 Clinical | Abbvie Inc | Solid tumours | Details |
| Recombinant anti-EGFR chimeric antibody (Harbin Pharmaceutical) | Phase 1 Clinical | Harbin Pharmaceutical Group Holding Co Ltd | Colorectal Neoplasms | Details | |
| recombinant EGF/CRM-197 vaccine (Shanghai Humantech Biotechnology) | Phase 1 Clinical | Shanghai Humantech Biotechnology Co Ltd | Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| anti-EGFRvIII CAR T-cell therapy (Beijing Marino) | Phase 1 Clinical | Beijing Marino Biotechnology Co Ltd | Glioblastoma | Details | |
| naputinib tosilate (Shenzhen Neptunus Bioengineering) | NEP-015 | Phase 1 Clinical | Shenzhen Neptunus Bioengineering Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| CXCR5 modified EGFR chimeric antigen receptor autologous T cells therapy | Phase 1 Clinical | Guangzhou Bio-Gene Technology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details | |
| Diakine-DK2 10 (EGFR) | DK210; DK-2-10 | Phase 1 Clinical | Deka Biosciences Inc | Kidney Neoplasms; Solid tumours; Head and Neck Neoplasms; Carcinoma, Renal Cell; Pancreatic Neoplasms; Skin Neoplasms; Neoplasms; Genital Neoplasms, Female; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| HLX-42 | HLX-42; HLX42 | Phase 1 Clinical | Hanlin Biotechnology Co Ltd | Solid tumours; Neoplasms | Details |
| CMAB-017 | CMAB-017 | Phase 1 Clinical | Taizhou Mabtech Pharmaceutical Co Ltd | Solid tumours | Details |
| JY-016 | JY-016 | Phase 1 Clinical | Beijing Jingyitaixiang Technology Development Co Ltd, Beijing Eastern Biotech Co Ltd | Solid tumours; Colorectal Neoplasms; Lung Neoplasms | Details |
| PF-08046052 | SGN-EGFRd2; LAVA-1223 | Phase 1 Clinical | Vu University Medical Center, Lava Therapeutics NV, Seagen Inc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
| CM-93 | CM-93 | Phase 1 Clinical | Shanghai Crimson Pharmaceutical Co Ltd | Glioblastoma | Details |
| BLU-701 | BLU-701; BLU 701 | Phase 1 Clinical | Blueprint Medicines Corp | Carcinoma, Bronchogenic; Bronchial Neoplasms; Thoracic Neoplasms; Carcinoma; Respiratory Tract Diseases; Neoplasms; Lung Diseases; Respiratory Tract Neoplasms; Neoplasms, Nerve Tissue; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
| CX-904 | CX-904 | Phase 1 Clinical | Amgen Inc, Cytomx Therapeutics Inc | Solid tumours; Neoplasms | Details |
| Cetuximab biosimilar (Humanwell Healthcare) | Phase 1 Clinical | Humanwell Healthcare (Group) Co Ltd | Colorectal Neoplasms | Details | |
| JS-212 | JS212; JS-212 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Solid tumours | Details |
| ALK-202 | ALK-202; ALK202 | Phase 1 Clinical | Shanghai Allink Biotherapeutics Co Ltd | Solid tumours; Neoplasm Metastasis | Details |
| Panitumumab biosimilar(Generium) | GNR-107 | Phase 1 Clinical | Generium Pharmaceuticals | Colorectal Neoplasms | Details |
| Sirotinib Maleate | XZP-5491 | Phase 1 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung | Details |
| BG-60366 | BG-60366 | Phase 1 Clinical | BeOne Medicines Ltd | Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Tomuzotuximab | GT-MAB-5.2-GEX | Phase 1 Clinical | Glycotope Gmbh | Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| SAR-446368 | AMX-525; SAR446368; SAR-446368; VIR-5525 | Phase 1 Clinical | Amunix Pharmaceuticals Inc | Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| DWP709 | DWP709; DWP-818-1 | Phase 1 Clinical | Daewoong Pharmaceutical Co Ltd | Epidermolysis Bullosa | Details |
| CMDE-005 | CMDE-005; CMDE005; CMD-E005 | Phase 1 Clinical | Zhejiang Shimai Pharmaceutical Co Ltd | Solid tumours | Details |
| BG-T187 | BG-T187; BGT187 | Phase 1 Clinical | BeOne Medicines Ltd | Solid tumours; Lung Neoplasms; Gastrointestinal Neoplasms | Details |
| KY-0301 | KY-0301 | Phase 1 Clinical | Novatim Immune Therapeutics (Zhejiang) Co Ltd | Solid tumours | Details |
| IBI-3001 | IBI-3001; IBI3001 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
| BL-B16D1 | BLB16D1; BL-B16D1 | Phase 1 Clinical | Baili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Breast Neoplasms | Details |
| HJ-002-03 | HJ-002-03; HJ00203 | Phase 1 Clinical | Jing Medicine Technology (Shanghai) Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| YL-221 | YL221; YL-221 | Phase 1 Clinical | MediLink Therapeutics Co Ltd | Solid tumours | Details |
| HS-10504 | HS10504; HS-10504 | Phase 1 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| BPI-520105 | BPI-520105; BPI520105 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours | Details |
| [14C]-PLB1004 | [14C]-PLB1004 | Phase 1 Clinical | Carcinoma, Non-Small-Cell Lung | Details | |
| FPI-2107 | [111In]-FPI-2107 | Phase 1 Clinical | Fusion Pharmaceuticals Inc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
| FPI-2053 | FPI-2053 | Phase 1 Clinical | Fusion Pharmaceuticals Inc, Astrazeneca Plc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
| KK-2260 | KK2260; KK-2260 | Phase 1 Clinical | Kyowa Kirin Co Ltd | Solid tumours; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
| TQB-2922 | TQB2922; TQB-2922 | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Neoplasms | Details |
| DM-005 | DM005; YH013; DM-005 | Phase 1 Clinical | Doma Biopharmaceutical (Suzhou) Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung | Details |
| FPI-2068 | [225Ac]-FPI-2068; FPI-2068 | Phase 1 Clinical | Fusion Pharmaceuticals Inc, Astrazeneca Plc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
| KY-1702 | KY-1702; KY1702 | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| SNC-109 | SNC109; SNC-109 | Phase 1 Clinical | Shanghai Simnova Biotechnology Co Ltd | Glioblastoma | Details |
| HSK-40118 | HSK40118; HSK-40118 | Phase 1 Clinical | Haisco Pharmaceutical Group Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| AZD9592 | AZD-9592; AZD9592 | Phase 1 Clinical | Astrazeneca Plc | Solid tumours; Head and Neck Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| JANX-008 | EGFR-TRACTr; JANX008; JANX-008 | Phase 1 Clinical | Janux Therapeutics Inc | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
| TAVO-412 | TAVO-412 | Phase 1 Clinical | Tavotek Biotherapeutics (Hong Kong) Ltd, Tuochuang Biotechnology (Jiangsu) Co Ltd | Solid tumours; Neoplasms | Details |
| NX-019 | NX-019 | Phase 1 Clinical | Nalo Therapeutics Inc | Neoplasms | Details |
| BCG-011 | DM-001; BCG-011 | Phase 1 Clinical | Biocytogen Pharmaceuticals (Beijing) Co Ltd | Solid tumours; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| QLH-11811 | QLH-11811; QLH11811 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| Losatuxizumab vedotin | ABBV-221; ABBV221 | Phase 1 Clinical | Abbvie Inc | Neoplasms | Details |
| EGFR/B7H3 CAR-T | EGFR/B7H3 CAR-T | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Triple Negative Breast Neoplasms; Lung Neoplasms | Details |
| DXC004A | DXC-004-A; DXC004A | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Head and Neck Neoplasms; Solid tumours; Lung Neoplasms | Details |
| BB-1705 | BB-1705 | Phase 1 Clinical | Bliss Biopharmaceutical (Hangzhou) Co Ltd | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
| CART-EGFR-IL13Ra2 | CART-EGFR-IL13Ra2; CAR-T-EGFR-IL-13-Ra-2 | Phase 1 Clinical | University Of Pennsylvania | Glioblastoma | Details |
| EGFR IL12 CART | Phase 1 Clinical | Colorectal Neoplasms | Details | ||
| ERAS-801 | ERAS-801; JGK-068S | Phase 1 Clinical | Regents Of The University Of California | Glioblastoma | Details |
| NIP-142 | NIP-142 | Phase 1 Clinical | National Institutes Of Pharmaceutical Research And Development Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| TAS-2940 | TAS-2940 | Phase 1 Clinical | Taiho Oncology Inc | Solid tumours; Glioblastoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| [111In] Panitumumab | Phase 1 Clinical | Stanford University | Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details | |
| BC-3448 | BC3448; BC-3448 | Phase 1 Clinical | Wuxi BioCity | Solid tumours | Details |
| ABBV-637 | ABBV-637 | Phase 1 Clinical | Abbvie Inc | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| M-1231 | M-1231 | Phase 1 Clinical | Emd Serono Research & Development Institute Inc, Merck Serono | Solid tumours; Esophageal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| HLX-35 | HLX-35; BNA035 | Phase 1 Clinical | Shanghai Henlius Biologics Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| WTS-004 | WTS-004 | Phase 1 Clinical | Hangzhou Wutong Tree Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| FCN-411 | FCN-411 | Phase 1 Clinical | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| ES-072 | ES-072 | Phase 1 Clinical | Zhejiang Bosheng Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| ZZ-06 | ZZ-06 | Phase 1 Clinical | Changchun Intellicrown Pharmaceutical Co Ltd | Solid tumours | Details |
| ABY-029 | ABY-029 | Phase 1 Clinical | Dartmouth College, Affibody Ab, Li-Cor Bioscience | Head and Neck Neoplasms; Sarcoma; Glioma | Details |
| Lifirafenib | BeiGene-283; BGB-283 | Phase 1 Clinical | BeOne Medicines Ltd | Solid tumours | Details |
| Cetuximab biosimilar (Enzene Biosciences) | Clinical | Enzene Biosciences Ltd | Carcinoma, Squamous Cell | Details | |
| VRN-11 | VRN11 | Clinical | Voronoi Inc | Carcinoma, Non-Small-Cell Lung | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Osimertinib Mesylate | AZD-9291; RDL94R2A16; AZD-9291 Mesylate; AZD9291 | Approved | Astrazeneca Plc | Tagrisso, 泰瑞沙 | United States | Carcinoma, Non-Small-Cell Lung | Astrazeneca Pharmaceutical Co Ltd | 2015-11-13 | Uterine Neoplasms; Multiple Myeloma; Breast Neoplasms; Prostatic Neoplasms; Meningeal Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Brain metastases; Endometrial Neoplasms; Urinary Bladder Neoplasms; Thyroid Neoplasms; Carcinoma, Squamous Cell; Lymphoma; Glioma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Melanoma; Uterine Cervical Neoplasms; Squamous Cell Carcinoma of Head and Neck; Head and Neck Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Neoplasm, Residual; Hematologic Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Rectal Neoplasms; Solid tumours; Stomach Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Adenocarcinoma of Lung; Skin Neoplasms; Glioblastoma; Neoplasms | Details |
| Menadione | Approved | Eli Lilly And Company | Kyrbax | United States | null | Vitamin K Deficiency Bleeding; Hypoprothrombinemias; Exanthema | Details | |||
| PX-070101 | PX-070101 | Approved | Praxis Pharmaceuticals | Colombia | Diabetic Foot | Praxis Pharmaceuticals | 2015-07-01 | Diabetic Foot | Details | |
| Cetuximab biosimilar (Shanghai Zhangjiang Biotechnology) | STI-001; CMAB-009 | Approved | Shanghai Zhangjiang Biotechnology Co Ltd | Enlituo | Mainland China | Colorectal Neoplasms | Taizhou Mabtech Pharmaceutical Co Ltd | 2024-06-18 | Neoplasms; Colorectal Neoplasms | Details |
| Cetuximab sarotalocan | RM-1929; ASP-1929 | Approved | Aspyrian Therapeutics | Akalux | Japan | Head and Neck Neoplasms | Rakuten Medical Inc | 2020-09-25 | Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
| Cetuximab | IMC-C255; BMS-564717; EMD-271786; C-255; GT-MAB-5.2; ch-225; LY-2939777; NSC-714692 | Approved | Bristol-Myers Squibb Company, Eli Lilly And Company, Merck Serono | 爱必妥, Erbitux | United States | Colorectal Neoplasms | Imclone Gmbh | 2004-02-12 | Adenocarcinoma, Mucinous; Sarcoma; Oropharyngeal Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Carcinoma, Mucoepidermoid; Neuralgia; Endometrial Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Laryngeal Neoplasms; Carcinoma, Squamous Cell; Glioma; Nasopharyngeal Carcinoma; Esophageal Squamous Cell Carcinoma; Paranasal Sinus Neoplasms; Mouth Neoplasms; Lip Neoplasms; Precancerous Conditions; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Tongue Neoplasms; Complex Regional Pain Syndromes; Nose Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Liver Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esthesioneuroblastoma, Olfactory; Carcinoma, Basal Cell; Granuloma, Lethal Midline; Pancreatic Neoplasms; Neoplastic Cells, Circulating; Hypopharyngeal Neoplasms; Colonic Neoplasms; Neoplasms; Neoplasms, Squamous Cell; Glioblastoma; Carcinoma, Verrucous; Salivary Gland Neoplasms; N | Details |
| Afatinib Dimaleate | BIBW-2992-MA2; BIBW-2992 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Gilotrif, Giotrif, Tovok, 吉泰瑞, Tomtovok | United States | Carcinoma, Non-Small-Cell Lung | C.H. Boehringer Sohn Ag & Co. Kg | 2013-07-12 | Glioma; Prostatic Neoplasms; Brain Neoplasms; Urethral Neoplasms; Urologic Neoplasms; Colorectal Neoplasms; Ureteral Neoplasms; Lung Neoplasms; Carcinoma, Squamous Cell; Breast Neoplasms; Uterine Neoplasms; Esophageal Squamous Cell Carcinoma; Gallbladder Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Neoplasm Metastasis; Hematologic Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Liver Diseases; Chordoma; Neuroectodermal Tumors; Neoplasms, Squamous Cell; Glioblastoma; Neoplasms; Renal Insufficiency; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma; Solid tumours; Head and Neck Neoplasms | Details |
| Epidermal growth factor biosimilar (RAS Lifesciences) | Approved | Ras Lifesciences | India | Ras Lifesciences | 2012-10-01 | Details | ||||
| Recombinant epidermal growth factor gel (Pavay Gene Pharmaceutical) | Approved | Guilin Huanuowei Gene Pharmaceutical Co Ltd | 易孚 | Mainland China | Skin Ulcer; Burns | Guilin Huanuowei Gene Pharmaceutical Co Ltd | 2002-12-23 | Skin Ulcer; Burns | Details | |
| Nimotuzumab | TheraCIMh-R3; YMB-1000; OSAG-10; KI-0502; KI-0501; DE-766; h-R3; OSAG-101; OSAG101 | Approved | Center Of Molecular Immunology, Cimym Biosciences | BIOMAb-EGFR, TheraCIM, 泰欣生, CIMAher, Theraloc, Taixinsheng | India | Head and Neck Neoplasms; Nasopharyngeal Neoplasms | null | 2006-07-21 | Nasopharyngeal Diseases; Carcinoma, Non-Small-Cell Lung; Esophageal Diseases; Uterine Cervical Neoplasms; Carcinoma, Squamous Cell; Glioma; Esophageal Squamous Cell Carcinoma; Colorectal Neoplasms; Nasopharyngeal Carcinoma; Neoplasms; Head and Neck Neoplasms; Nasopharyngeal Neoplasms; Pancreatic Neoplasms; Pancreatic neuroendocrine tumors (pNET); Anus Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Solid tumours | Details |
| Recombinant epidermal growth factor (Center for Genetic Engineering and Biotechnology/Praxis Pharmaceuticals) | Approved | Praxis Pharmaceuticals, Center For Genetic Engineering And Biotechnology | Heberprot-P | Cuba | Diabetic Foot | null | 2007-09-01 | Diabetic Foot | Details | |
| Erlotinib Hydrochloride | CP-358774-01; RO-0508231; NSC-718781; CP-358774; RG-1415; OSI-774; R-1415 | Approved | Genentech Inc | Tarceva, 特罗凯 | EU | Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Cheplapharm Registration GmbH | 2004-11-18 | Head and Neck Neoplasms; Leukemia, Promyelocytic, Acute; Solid tumours; Adenomatous Polyposis Coli; Kidney Neoplasms; Ependymoma; Liver Neoplasms; HIV Infections; Medulloblastoma; Brenner Tumor; Ovarian Neoplasms; Rhabdomyosarcoma; Neoplasm Recurrence, Local; Cystadenocarcinoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Rectal Neoplasms; Cystadenocarcinoma, Serous; Polycythemia Vera; Anus Neoplasms; Granuloma, Lethal Midline; Esthesioneuroblastoma, Olfactory; Carcinoma, Basal Cell; Cystadenocarcinoma, Mucinous; Pancreatic Neoplasms; Neoplasms; Salivary Gland Neoplasms; Myelodysplastic Syndromes; Colonic Neoplasms; Leukemia, Myelomonocytic, Chronic; Glioblastoma; Hypopharyngeal Neoplasms; Carcinoma, Verrucous; Nose Neoplasms; Nasopharyngeal Neoplasms; Carcinoma, Ovarian Epithelial; Adenocarcinoma of Lung; Leukemia, Myelomonocytic, Acute; Carcinoma, Transitional Cell; Liver Cirrhosis; Pachyonychia Congenita; Skin Neoplasms; Urinary Bladder Neoplasm | Details |
| Gefitinib | ZD-1839 | Approved | Astrazeneca Plc | 易瑞沙, Iressa | Japan | Carcinoma, Non-Small-Cell Lung | Astrazeneca Pharmaceutical Co Ltd | 2002-07-05 | Carcinoma, Mucoepidermoid; Lip Neoplasms; Mouth Neoplasms; Carcinoma, Squamous Cell; Glioma; Lung Neoplasms; Adenocarcinoma, Bronchiolo-Alveolar; Gliosarcoma; Astrocytoma; Oropharyngeal Neoplasms; Laryngeal Neoplasms; Colorectal Neoplasms; Gastrinoma; Carcinoma, Basosquamous; Brain Neoplasms; Medullary thyroid cancer (MTC); Nasopharyngeal Carcinoma; Prostatic Neoplasms; Urethral Neoplasms; Breast Neoplasms; Neoplasms, Germ Cell and Embryonal; Uterine Cervical Neoplasms; Gastrointestinal Neoplasms; Somatostatinoma; Carcinoma, Hepatocellular; Breast Neoplasms, Male; Tongue Neoplasms; Thyroid Cancer, Papillary; Laryngeal Diseases; Neoplasm Metastasis; Glucagonoma; Carcinoma, Non-Small-Cell Lung; Neoplasms, Neuroepithelial; Endometrial Neoplasms; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Paranasal Sinus Neoplasms; Brain metastases; Thyroid Neoplasms; Stomach Neoplasms; Glioblastoma; Vipoma; Carcinoma, Islet Cell; Insulinoma; Carcinoma, Basal Cell; Parathyroid Neoplasms; Granuloma, Lethal Midline; Squamo | Details |
| Brigatinib | AP-26113 | Approved | Ariad Pharmaceuticals Inc | Alunbrig, ALUNBRIG | United States | Carcinoma, Non-Small-Cell Lung | Takeda Pharmaceuticals USA Inc | 2017-04-28 | Solid tumours; Ependymoma; Carcinoma; Neoplasms; Neurofibromatosis 2; Myofibroma; Lymphoma, Large-Cell, Anaplastic; Granuloma, Plasma Cell; Lung Neoplasms; Brain metastases; Carcinoma, Non-Small-Cell Lung; Sarcoma, Kaposi; Neurilemmoma; Neuroma, Acoustic; Meningioma | Details |
| Recombinant Human Epidermal Growth Factor Derivative (Shenzhen Wastin Genetech) | rEGF | Approved | Shenzhen Watsin Genetech Ltd | 金因肽, GeneTime | Mainland China | Wounds and Injuries | Shenzhen Watsin Genetech Ltd | 2001-01-01 | Wounds and Injuries | Details |
| Nepidermin | DWP-401 | Approved | Daewoong Pharmaceutical Co Ltd | Easyef | South Korea | Alopecia; Diabetic Foot | Daewoong Pharmaceutical Co Ltd | 2001-01-01 | Diabetic Foot; Alopecia; Dry Eye Syndromes | Details |
| Icotinib Hydrochloride | BPI-2009H; BPI-2009C | Approved | Betta Pharmaceuticals Co Ltd | 凯美纳, Conmana | Mainland China | Carcinoma, Non-Small-Cell Lung | Betta Pharmaceuticals Co Ltd | 2011-06-07 | Solid tumours; Esophageal Neoplasms; Bronchial Neoplasms; Stomach Neoplasms; Adenocarcinoma of Lung; Neurofibromatosis 2; Psoriasis; Nasopharyngeal Carcinoma; Metastatic breast cancer; Lung Neoplasms; Carcinoma, Squamous Cell; Brain metastases; Carcinoma, Non-Small-Cell Lung; Neuroma, Acoustic; Adenocarcinoma | Details |
| Recombinant human EGF conjugated vaccine | Approved | Biotech Pharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung | Details | ||||||
| Recombinant epidermal growth factor (Bharat Biotech) | REGEN-D 60; REGEN-D 150 | Approved | Bharat Biotech International Ltd | India | Diabetic Foot; Burns | Bharat Biotech International Ltd | 2005-01-01 | Diabetic Foot; Burns | Details | |
| Lazertinib | JNJ-73841937; JNJ-1937; GNS-1480; YH-25448 | Approved | Oscotec Inc, Janssen Biotech Inc, Yuhan Corp | Leclaza, Lazcluze | South Korea | Carcinoma, Non-Small-Cell Lung | Yuhan Corp | 2021-01-18 | Hepatic Insufficiency; Carcinoma, Non-Small-Cell Lung | Details |
| Recombinant epidermal growth factor biosimilar (Elea) | r-hu-EGF | Approved | Elea | Argentina | Diabetic Foot; Burns | Elea | 2015-01-01 | Diabetic Foot; Burns | Details | |
| Recombinant Human Epidermal Growth Factor Derivative Eye Drops (Shenzhen Wastin Genetech) | Approved | Shenzhen Watsin Genetech Ltd | 金因舒, GeneSoft | Mainland China | Corneal Diseases | Shenzhen Watsin Genetech Ltd | 2004-01-21 | Corneal Diseases | Details | |
| Necitumumab | LY-3012211; IMC-11F8 | Approved | Eli Lilly And Company | Portrazza | United States | Carcinoma, Non-Small-Cell Lung | Eli Lilly And Co (Ireland) Ltd | 2015-11-24 | Solid tumours; Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
| Cetuximab N01 | KL-A140; KLA140; A-140; KL-140; KLA-140 | Approved | Sichuan Kelun Pharmaceutical Co Ltd | 达泰莱 | Mainland China | Colorectal Neoplasms | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | 2025-01-24 | Rectal Neoplasms; Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Adenocarcinoma | Details |
| Panitumumab | ABX-0303; E7.6.3; ABX-10221; AMG-954; ABX-EGF | Approved | Amgen Inc | Vectibix | United States | Colorectal Neoplasms | Amgen Inc | 2006-09-27 | Malignant Carcinoid Syndrome; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Exanthema; Neoplasm Metastasis; Glioma; Adenoma, Pleomorphic; Lung Neoplasms; Carcinoma, Squamous Cell; Colorectal Neoplasms; Brain Neoplasms; Prostatic Neoplasms; Head and Neck Neoplasms; Pancreatic Neoplasms; Salivary Gland Neoplasms; Neoplasms; Colonic Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Esophageal Neoplasms; Rectal Neoplasms; Kidney Neoplasms; Solid tumours | Details |
| Neratinib Maleate | CAN-030; PB-272; HKI-272; PF-0528767; WAY-179272 | Approved | Pfizer Inc | Nerlynx, 贺俪安, 汉奈佳 | United States | Breast Neoplasms | Puma Biotechnology Inc | 2017-07-17 | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Hepatic Insufficiency; Colorectal Neoplasms; Lung Neoplasms; Metastatic breast cancer; Brain metastases; Carcinoma, Non-Small-Cell Lung | Details |
| Cetuximab biosimilar (CinnaGen) | Approved | Cinnagen | Iran | Colorectal Neoplasms | Cinnagen | 2017-01-01 | Colorectal Neoplasms | Details | ||
| Lapatinib Ditosylate Hydrate | GW-572016; GW-572016F; GW-2016 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | Tykerb, Tyverb, 泰立沙, Tykerb/Tyverb | United States | Breast Neoplasms | Novartis Pharma Ag | 2007-03-13 | Lymphoma; Gliosarcoma; Bile Duct Neoplasms; Oropharyngeal Neoplasms; Carcinoma, Mucoepidermoid; Carcinoma, Acinar Cell; Brain metastases; Lung Neoplasms; Glioma; Gallbladder Neoplasms; Neoplasms, Gonadal Tissue; Carcinoma, Squamous Cell; Mouth Neoplasms; Lip Neoplasms; Endometrial Neoplasms; Astrocytoma; Paranasal Sinus Neoplasms; Laryngeal Neoplasms; Metastatic breast cancer; Uterine Cervical Neoplasms; Adenocarcinoma; Melanoma; Tongue Neoplasms; Breast Neoplasms, Male; Carcinoma, Hepatocellular; Neoplasm Metastasis; Laryngeal Diseases; Neuroma, Acoustic; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Carcinoma, Ovarian Epithelial; Liver Neoplasms; Ependymoma; Medulloblastoma; Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Abdominal Neoplasms; Carcinoma, Renal Cell; Carcinoma; Neoplasms; Salivary Gland Neoplasms; Glioblastoma; Head and Neck Neoplasms; Pancreatic Neoplasms; Carcinoma, Verrucous; Hypopharyngeal Neoplasms; Nose N | Details |
| Recombinant epidermal growth factor (Shanghai Haohai ) | Approved | Shanghai Haohai Biological Technology Co Ltd | 康合素 | Mainland China | Burns | Shanghai Haohai Biological Technology Co Ltd | 2001-01-01 | Burns | Details | |
| Amivantamab | JNJ-61186372; JNJ-372; JNJ-6372; CNTO4424; CNTO-4424 | Approved | Johnson & Johnson Innovative Medicine, Genmab A/S | RYBREVANT | United States | Carcinoma, Non-Small-Cell Lung | Janssen Biotech Inc | 2021-05-21 | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Glioblastoma; Carcinoma, Adenoid Cystic; Colorectal Neoplasms; Glioma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Hepatocellular | Details |
| Recombinant epidermal growth factor drop (Pavay Gene Pharmaceutical) | Approved | Guilin Huanuowei Gene Pharmaceutical Co Ltd | 易贝 | Mainland China | Corneal Diseases | Guilin Huanuowei Gene Pharmaceutical Co Ltd | 2002-04-12 | Corneal Diseases; Xerophthalmia | Details | |
| Pyrotinib Maleate | BLTN; HTI-1001; SHR-1258 | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾瑞妮 | Mainland China | Breast Neoplasms | Jiangsu Hengrui Medicine Co Ltd | 2018-08-12 | Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Adenocarcinoma of Lung; Neoplasms; Breast Neoplasms; Bile Duct Neoplasms; Metastatic breast cancer; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms | Details |
| Dacomitinib | PF-00299804-03; PF-00299804-3; PF-00299804; PF-299804; PF-299; PF-804 | Approved | Pfizer Inc | Vizimpro | United States | Carcinoma, Non-Small-Cell Lung | Pfizer Inc | 2018-09-27 | Colorectal Neoplasms; Adenocarcinoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Mouth Neoplasms; Lung Neoplasms; Carcinoma, Squamous Cell; Penile Neoplasms; Head and Neck Neoplasms; Brain Neoplasms; Liver Diseases; Carcinoma, Large Cell; Glioblastoma; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Solid tumours | Details |
| Mouse epidermal growth factor (Hangzhou Tianmushan Pharmaceutical) | Approved | Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd | 一夫 | Wounds and Injuries | Details |
Product Reviews
z***g2025-12-03
0People LikeACRO's Human IGF-1R protein has high purity, low endotoxin, very low background in cell experiments, stable and accurate binding activity EC50, very small batch differences, professional after-sales service, fast shipping, is an essential product for signaling pathway research!- G***I2025-11-07 0People LikeUsed this product for ELISA experiments, mainly for coating 96-well plates. The results met expectations. The results are consistent with expectations, the fitting curve is a standard four-parameter curve, very good.
- G***I2025-11-07 0People LikeUsed this product for ELISA experiments, mainly for coating 96-well plates. The results met expectations. Compared with other companies, ACRO protein stability is good, will purchase more in the future.
Load More
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland